anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses special powder for treating a dental ulcer, belonging to a traditional Chinese medicine powder prescription in the field of medical treatment. The special powder aims at solving the problem that the traditional Chinese medicine is not ideal in curative effect on the dental ulcer at present. The main points of the technical scheme are as follows: the prescription disclosed by the invention comprises the following components by weight: 30g of indigo naturalis, 30g of borneol, 20g of rosin, 20g of sodium borate, 10g of coptis chinensis, 20g of frankincense and 20g of myrrh. All medicines are sieved by a 120 mesh sieve after being crushed, and then prepared into the traditional Chinese medicine powder. A right amount of powder is taken when being used, and is applied to the affected part in a blowing manner, thereby achieving the target of treating the dental ulcer. The powder is mainly used for treating the dental ulcer.
The transmission of sexually transmitted diseases (STDs), including HIV, is a major public health concern, especially among minority groups in the United States. Although STDs are prevalent across all racial and ethnic groups in the United States, the rate of STD infection is disproportionately higher for African Americans than for white Americans. African Americans have higher rates of HIV, chlamydia, gonorrhea, syphilis, and herpes than white Americans. An important part of the prevention process is early education on HIV to reduce sexual-risk behavior and to promote safe sexual practices. Interventions are needed in a variety of settings to extensively address African Americans' risk of STDs, including HIV. Although most HIV/STD risk-reduction interventions are conducted at the individual level, a couple-based approach may be more effective and consistent with cultural values. This study will compare the effectiveness of the Eban HIV/STD Risk Reduction Intervention with the Eban Health Promotion Intervention in reducing the risk of STDs among African-American HIV-serodiscordant heterosexual couples.

Participation in this study will last 12 months. All participants will first undergo baseline assessments that will consist of questionnaires and biospecimen collection for STD testing. Participants will then be assigned randomly to one of two treatment groups: the Eban HIV/STD Risk Reduction Intervention group or the Eban Health Promotion Intervention group. Both groups will participate in weekly 2-hour sessions over 8 weeks. The sessions will include couple and group sessions led by trained male and female co-facilitators. The Eban HIV/STD Risk Reduction Intervention sessions will focus on the couple and will teach the couple about communication skills. The approach will draw upon social cognitive theory, an ecological framework, and HIV/STD risk-reduction research with inner-city African-American populations. The Eban Health Promotion Intervention sessions will focus on the individual and will provide factual information on health, screening, exercise, diet management, and medication adherence. Follow-up visits for all participants will occur at Months 3, 6, and 12 and will include repeat baseline assessments.
Noom behavioural weight loss program subscription for 1 year. Subjects will also be provided with the OneTouch Verio Reflect glucose meter and the OneTouch Reveal (OTR) mobile diabetes app.
Serious adverse reactions that may be associated with ROXICET use include respiratory depression, apnea, respiratory arrest, circulatory depression, hypotension, and shock (see OVERDOSAGE).

The most frequently observed non-serious adverse reactions include lightheadedness, dizziness, drowsiness or sedation, nausea, and vomiting. These effects seem to be more prominent in ambulatory than in nonambulatory patients, and some of these adverse reactions may be alleviated if the patient lies down. Other adverse reactions include euphoria, dysphoria, constipation, and pruritus.

Hypersensitivity reactions may include: Skin eruptions, urticarial, erythematous skin reactions. Hematologic reactions may include: Thrombocytopenia, neutropenia, pancytopenia, hemolytic anemia. Rare cases of agranulocytosis has likewise been associated with acetaminophen use. In high doses, the most serious adverse effect is a dose-dependent, potentially fatal hepatic necrosis. Renal tubular necrosis and hypoglycemic coma also may occur.

Other adverse reactions obtained from postmarketing experiences with ROXICET are listed by organ system and in decreasing order of severity and/or frequency as follows:
The present invention provides methods and compositions for the inhibition of proliferation rate of target cells, for example tumor cells. In particular, a nucleic acid encoding a connexin protein, fragment, derivative or analog thereof can be incorporated into a target cell. Expression of the nucleic acid sequence encoding the connexin protein, fragment, derivative or analog thereof, particularly connexin 43 and non-phosphorylated connexin 43, reduces the level of bcl-2 expression in the cells thereby inducing the cells to enter apoptosis. Connexin protein, fragments, derivatives, or analogs thereof can also be administered to the cell population to reduce bcl-2 expression inducing apoptosis in the cell population. It has further been found that the addition of an antagonist of MCP-1 activity can enhance the effects of connexin on tumor cell proliferation. Also, the prognosis of a subject undergoing standard chemotherapy can be assessed by correlating the expression levels of connexin and bcl-2.
Acquired Brain Injury resulting from a TBI or CVA is a primary cause of chronic disability and unemployment, resulting in significant health, societal, and financial burden. The Brain Injury Neurorehabilitation Project is part of a systematic effort to study ABI in Cyprus. It is an umbrella project designed to generate cutting edge research in brain injury and cognitive rehabilitation that will advance neurorehabilitation research. Patients with TBI and strokes are often faced with cognitive and behavioral difficulties that interfere with their ability to return to productive living, thus contributing to unemployment, social isolation and low quality of life for decades post injury. The scientific objectives will address the aforementioned challenge. First, the project will establish the first TBI surveillance system in Cyprus and implement epidemiologically-principled and systematic data collection from large cohorts across the severity continuum. It will integrate neuropsychological, lifestyle, injury, imaging, genetic, and biological data using state of the art computational methods and quantitatively assess the exact contribution of critical variables to brain injury recovery. Second, the project will determine the effectiveness of a theory-driven neurocognitive therapy program, the Categorization Program (CP) in combination with a social-communication training during the chronic phase of the recovery process. It is hypothesized that the combination of remedial cognitive and social-communication training will yield improvement in functioning with sustainable long term effects. Additionally, the project will implement non-invasive brain stimulation (NIBS) in combination with the social-communication intervention to determine the utility of NIBS and specifically tDCS, in improving cognitive performance and psychosocial functioning. Through innovative research and development of new methods and technologies, the project will advance the State-of-the-Art by producing cutting edge research with international impact while contributing to the development of personalized medicine and improvement of rehabilitation outcomes and reduction of disability in Cyprus.
The invention relates to flower and grass perfume and belongs to the technical field of cosmetics. The flower and grass perfume is prepared from the following raw materials according to a weight ratio through mixing and soaking: 90%-95% of aromatic glutinous rice wine, 1%-2% of osmanthus fragrans, 1%-2% of mint, 1%-3% of rose and 2%-3% of scabish, wherein osmanthus fragrans, mint, rose and scabish are dried. The perfume used as a beauty product can emit a strong, long-lasting and pleasant aroma and can increase aesthetic feeling and attraction of a user. With the improvement of living standards and transformation of consumption concepts, the perfume becomes a daily product for people from a luxury product. The aroma of the perfume used as an intangible business card of the user can present unique personality and charisma of the user, and perfect and enrich cultural image of the user, so that the perfume is deeply popular in all kinds of crowds. The flower and grass perfume provided by the invention is fragrant in smell, long-lasting and soft in aroma, non-oily, non-irritant, friendly to skin, good in skin-touch, air permeability and spreadability, and further has a healthcare effect.
Artificial light at night (ALAN) is known to affect organisms in terrestrial ecosystems and adjacent litoral habitats. In the present study, we tested the effect of ALAN on the spatial distribution of organisms in open waters, using the insect larvae of Chaoborus flavicans as an example. During the day C. flavicans typically hide from visually hunting fish in deep, dark, anoxic waters. On safer nights, they forage in rich subsurface waters. Nighttime field tests revealed that light from an HPS street lamp mounted on a boat anchored in open water attracted planktivorous fish, but deterred planktonic Chaoborus from rich but risky surface waters. Chaoborus did not descend to the safest, anoxic hypolimnion, but remained in hypoxic mid-depth metalimnion, which does not appear to be a perfect refuge. Neither light gradient nor food distribution fully explained their mid-depth residence under ALAN conditions. A further laboratory test revealed a limited tolerance of C. flavicans to anoxia. Half of the test larvae died after 38 h at 9 °C in anoxic conditions. The trade-off between predation risk and oxygen demand may explain why Chaoborus did not hide in deep anoxic waters, but remained in the riskier metalimnion with residual oxygen under ALAN conditions.
The invention relates to medicine, more specifically to dressing means used for stopping capillary, diffusion and parenchymatous haemorrhages and for closing wounds streaming blood. The aim of the invention is to produce dressings exhibiting high hemostatic and sanitary properties and an increased sorption and atraumatic action. The textile carrier of the inventive dressing is embodied in the form of a knitted or non-woven material having a sorption capacity for water ranging from 9 to 20 g/g. Ferrous gluconate or ferrous lactate whose content into the dressing ranges from 0.4 to 3.0 mg/cm2 are used as hemostatic substances. The textile carrier is coated with a polyethylene glycol layer whose molecular mass ranges from 200 to 1200 and which is applied to said carrier in a quantity ranging from 0.02 to 0.3 g/cm2. Said hemostatic dressing is provided with an additional atraumatic layer embodied in the form of a perforated film or a net made of a hydrofuge polymer, for example polypropylene, said additional layer being arranged on the side of a traumatic surface. The inventive hemostatic dressing contains an antimicrobial preparation within the range between 0.03 and 0.3 mg/cm2.
A method for facilitating medical admissions includes ascertaining an understood language, accessing a database on an electronic device configured to communicate with a patient, selecting a translation of a question, and communicating the translation to the patient. The patient provides a response to the question to a medical professional without a translator. A system for facilitating medical admissions includes a database of prerecorded question translations by medical professionals and response cues. Potential responses to a question are limited to predetermined choices. Trust ratings are associated with the translations. Response cues provide answers to the questions to be communicated to a medical professional without a translator. A system for facilitating medical admissions includes reference information and a database containing closed-ended questions and translations. The reference information includes a translating medical professional's expertise and fluent language. Each translation is provided by a medical professional and reviewed by other medical professionals.
Muscle-wasting and disease-related malnutrition are highly prevalent in patients with chronic liver diseases (CLD) as well as in liver transplant (LT) candidates. Alterations of body composition (BC) such as sarcopenia, myosteatosis and sarcopenic obesity and associated clinical frailty were tied to inferior clinical outcomes including hospital admissions, length of stay, complications, mortality and healthcare costs in various patient cohorts and clinical scenarios. In contrast to other inherent detrimental individual characteristics often observed in these complex patients, such as comorbidities or genetic risk, alterations of the skeletal muscle and malnutrition are considered as potentially modifiable risk factors with a major clinical impact. Even so, there is only limited high-level evidence to show how these pathologies should be addressed in the clinical setting. This review discusses the current state-of-the-art on the role of BC assessment in clinical outcomes in the setting of CLD and LT focusing mainly on sarcopenia and myosteatosis. We focus on the disease-related pathophysiology of BC alterations. Based on these, we address potential therapeutic interventions including nutritional regimens, physical activity, hormone and targeted therapies. In addition to summarizing existing knowledge, this review highlights novel trends, and future perspectives and identifies persisting challenges in addressing BC pathologies in a holistic way, aiming to improve outcomes and quality of life of patients with CLD awaiting or undergoing LT.
<P>PROBLEM TO BE SOLVED: To provide a method and composition for inducing weight loss and maintaining optimum weight.  <P>SOLUTION: An agent is administered that stimulates carnitine palmitoyl transferase-1 (CPT-1) activity. The method does not require inhibition of fatty acid synthesis. The method selectively enhances fatty acid oxidation, increases energy production, and reduces adiposity while preserving lean body mass through pharmacological stimulation of (CPT-1) activity. Preferably, the agent is administered in an amount sufficient to increase fatty acid oxidation, and also in an amount sufficient to antagonize malonyl CoA inhibition of CPT-1.  <P>COPYRIGHT: (C)2010,JPO&INPIT
J0 to J42: once a week, Mepitel® and amniotic membrane (one or several depending on the graft size, so that the ulcer was completely covered with MAH). The last amniotic membrane is left in place.
PURPOSE: Postoperative thyroglobulin (Tg) generally serves as a biomarker to monitor the recurrence or persistence of differentiated thyroid cancer (DTC), whereas it constrains to interference from anti-thyroglobulin antibody (TgAb). This study aimed to determine the value of postoperative TgAb as a surrogate for monitoring tumor status in DTCs with positive TgAb after successful radioactive iodine (RAI) remnant ablation.
METHODS: We retrospectively enrolled DTC patients with positive (≥40 IU/mL, Roche) postoperative TgAb measurements. An index of TgAb change (ΔTgAb) was defined to describe the TgAb decrease rate. DTC status was defined as either no evidence of disease (NED) or persistent/recurrent disease (PRD). Univariate and multivariate binary logistic analyses were used to identify the independent risk factors of PRD. Receiver operating characteristic (ROC) curves were performed to determine the optimal cutoff values of each risk factor, and DeLong's test was conducted to compare their predictive powers. Kaplan-Meier curves were used to assess the impact of different TgAb trends in the first year on progression-free survival.
RESULTS: Of the 232 patients enrolled, the median diagnosis age was 34 years (range, 18-62 years), with a male-to-female ratio of 1:4.66 (41/191). Among them, after a median follow-up of 44 months (range, 4-128 months),183 (78.87%) patients were evaluated as NED, while the other 49 (21.12%) had either persistent (n = 25) or recurrent disease (n = 24). Multivariate regression showed that ΔTgAb (P < 0.001) and lymph node metastasis (LNM) rate (P = 0.009) were independently relevant to the presence of PRD, with optimal cutoff values of 47.0% and 35.1%, respectively. It is important to note that there is a high negative predictive value (96.93%) of ΔTgAb with the cutoff of 47.0%. DeLong's test showed that ΔTgAb alone and the combination of ΔTgAb and LNM rate were significantly greater than the isolated LNM rate (both P < 0.001) in predicting NED, while there was no statistical difference of the predictive power between ΔTgAb and the combination (P = 0.203). Additionally, patients with ΔTgAb >47.0% had longer progression-free survival than those with ΔTgAb ≤47.0% (not reached vs. 50 months, P < 0.001), and those with ΔTgAb >47.0% or negative conversion within the first year after RAI ablation had longer progression-free survival.
CONCLUSION: Our study suggested that ΔTgAb could serve as a valuable indicator of disease status in DTC patients with positive TgAb. A ΔTgAb of >47.0% is conducive to identify those with NED and may help to obviate their overtreatment. The decrease rate and negative conversion of TgAb in the first year were good predictors of disease-free survival in patients.
PURPOSE: To enhance an effect as gastric antiacid, antigas and antiflatulent compsns. by compounding water soluble aggregated maltodextrin and a liquid non-aqueous antifoaming or defoaming granular compd., thereby preparing a compsn. CONSTITUTION: The antifoaming or defoaming mixture is prepd. as the granular mixture by compounding the liquid non-aqueous antifoaming or defoaming granular compd. or compsn. with the aggregated maltodextrin. The granular mixture having a grain size below 850 μis adequate. The more adequate example of the liquid non-aqueous antifoaming or defoaming compd. is dimeticone. The antigas or antiflatulent compsn. for intake is prepd. by compounding 50 to 90 wt.% water soluble aggregated maltodextrin and 50 to 10 wt.% dry granular compd. of the dimeticone.
Computer program C 8 + treatment as usual. Subjects in the intervention group will be playing a special computer program C8 for 40 min a day, 6 times a week for 8 weeks in addition to treatment as usual.
Cyclobenzaprine hydrochloride is a white, crystalline tricyclic amine salt with the empirical formula C20H21 N•HCl and a molecular weight of 311.9. It has a melting point of 217°C, and a pKa of 8.47 at 25°C. It is freely soluble in water and alcohol, sparingly soluble in isopropanol, and insoluble in hydrocarbon solvents. If aqueous solutions are made alkaline, the free base separates. Cyclobenzaprine HCl is designated chemically as 3-(5H -dibenzo[a,d] cyclohepten-5-ylidene)-N, N-dimethyl-1-propanamine hydrochloride, and has the following structural formula:

Cyclobenzaprine hydrochloride is supplied as 5 mg and 10 mg tablets for oral administration.

Cyclobenzaprine hydrochloride tablets contain the following inactive ingredients: colloidal silicon dioxide, corn starch, hypromellose, lactose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, and propylene glycol.
PURPOSE: To provide an oral compsn. contains specific phosphopeptide and an antidental calculus agent consisting of water-soluble polyphosphate and/or water-soluble zincate which effectively suppress dental calculus formation by treating the teeth in the mouth. CONSTITUTION: This oral compsn. contains the effective amt. of the phosphopeptide having 5 to 30 pieces of amino acids including the amino acid sequence expressed by the formula A-B-C-D-E (A to E are phosphoserine, phosphothreonine, phosphotyrosine, phosphohistidine, glutamate and aspartate) or its salts and the effective amt. of the water-soluble polyphosphate and the water-soluble zincate and suppresses the dental calculus by treating the teeth in the mouth. The phosphopeptide is preferably obtd. from casein and is more preferably the phosphopeptide having the amino acid sequence of formula I or the amino acid sequence of formula II. The water-soluble polyphosphate is preferably alkaline metal polyphosphate. The water-soluble zincate is preferably zinc citrate. The oral compsn. is a liquid tooth polishing agent, intraoral detergent or toothpaste.
Myocardial injury and cardiovascular dysfunction are the most common complications of sepsis, and effective therapeutic candidate is still lacking. This study aims to investigate the protective effect of oxycodone in myocardial injury of lipopolysaccharide-induced sepsis and its related signalling pathways. Wild-type and nuclear factor erythroid 2-related factor 2 (Nrf2)-knockout mice, as well as H9c2 cardiomyocytes cultures treated with lipopolysaccharide (LPS) were used as models of septic myocardial injury. H9c2 cardiomyocytes culture showed that oxycodone protected cells from pyroptosis induced by LPS. Mice model confirmed that oxycodone pretreatment significantly attenuated myocardial pathological damage and improved cardiac function demonstrated by increased ejection fraction (EF) and fractional shortening (FS), as well as decreased cardiac troponin I (cTnI) and creatine kinase isoenzymes MB (CK-MB). Oxycodone also reduced the levels of inflammatory factors and oxidative stress damage induced by LPS, which involves pyroptosis-related proteins including: Nod-like receptor protein 3 (NLRP3), Caspase 1, Apoptosis-associated speck-like protein contain a CARD (ASC), and Gasdermin D (GSDMD). These changes were mediated by Nrf2 and heme oxygenase-1 (HO-1) because Nrf2-knockout mice or Nrf2 knockdown in H9c2 cells significantly reversed the beneficial effect of oxycodone on oxidative stress, inflammatory responses and NLRP3-mediated pyroptosis. Our findings yielded that oxycodone therapy reduces LPS-induced myocardial injury by suppressing NLRP3-mediated pyroptosis via the Nrf2/HO-1 signalling pathway in vivo and in vitro.
Capsule vancomycin 125 mg x 4 times daily p.o. for 7-14 days followed by Fecal Microbiota Transplantation with 200 ml fecal suspension administrated with a rectal catheter.
Participants performed 30 minutes of treadmill walking at 65% of the age-predicted maximum heart rate. The exercise started 15 minutes after the 75-g oral glucose intake.
Recent studies indicate that anti-factor-Xa inhibition with low-dose rivaroxaban may have a role in the reduction of ischemic recurrences in patients with atherosclerotic disease manifestations. In the COMPASS trial, patients with stable coronary or peripheral artery disease and no indication for oral anticoagulation or dual antiplatelet therapy (DAPT) were randomized to rivaroxaban 2.5 mg bid in combination with aspirin, rivaroxaban 5 mg bid monotherapy or aspirin monotherapy. The study showed a significant 24% relative reduction in ischemic outcomes with rivaroxaban 2.5 mg bid plus aspirin combination strategy compared with aspirin alone. These observations have raised practical considerations on how to implement the results of the COMPASS trial in clinical practice particularly for patients who are completing a minimum duration of DAPT and contemplating between continuing with a DAPT regimen versus switching to a dual pathway inhibition (DPI) regimen with aspirin plus rivaroxaban. Therefore, the objectives of this investigation are to assess the feasibility of switching from a DAPT to DPI regimen and to compare the pharmacodynamic profiles of these treatment regimens. This will be a prospective study conducted in cohorts of patients with CAD on treatment per standard of care with DAPT. Patients will be randomized to either maintain DAPT or to DPI. DPI consists in treatment with aspirin (81mg/qd) plus rivaroxaban (2.5mg/bid).